Literature DB >> 22776238

Guidelines for the management of hemophilia.

A Srivastava1, A K Brewer, E P Mauser-Bunschoten, N S Key, S Kitchen, A Llinas, C A Ludlam, J N Mahlangu, K Mulder, M C Poon, A Street.   

Abstract

Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence-based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion-transmitted infections. By compiling these guidelines, the World Federation of Hemophilia aims to assist healthcare providers seeking to initiate and/or maintain hemophilia care programs, encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776238     DOI: 10.1111/j.1365-2516.2012.02909.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  420 in total

1.  Hemophilia Management and Follow-up: Role of Radiological and Functional Assessment of the Disease Severity.

Authors:  Arun Kumar Gupta; Manisha Jana
Journal:  Indian J Pediatr       Date:  2015-09-24       Impact factor: 1.967

2.  Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.

Authors:  Katalin Kis-Toth; Gaurav Manohar Rajani; Allison Simpson; Kate L Henry; Jennifer Dumont; Robert T Peters; Joe Salas; Christine Loh
Journal:  Blood Adv       Date:  2018-11-13

3.  Extended Stability and Sterility of Antihemophilic Factor Human.

Authors:  Sarah Shields; Abby Kim; Joshua Elder
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

4.  [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].

Authors:  Jin-Mu Zhuang; Xue-Yan Sun; Xuan Zhou; Zhu-Qin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

5.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

6.  Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery.

Authors:  Ron Aa Mathôt; Marjon H Cnossen; Tim Preijers; Britta Ap Laros-vanGorkom
Journal:  BMJ Case Rep       Date:  2019-01-14

7.  Surgery in patients with congenital factor VII deficiency: A single center experience.

Authors:  Shin-Hee Kim; Young Shil Park; Kee-Hwan Kwon; Jae Hoon Lee; Kwang Chul Kim; Myung Chul Yoo
Journal:  Korean J Hematol       Date:  2012-12-24

8.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

9.  TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Authors:  Osman N Yogurtcu; Zuben E Sauna; Joseph R McGill; Million A Tegenge; Hong Yang
Journal:  AAPS J       Date:  2019-08-02       Impact factor: 4.009

Review 10.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.